Followers | 30 |
Posts | 3402 |
Boards Moderated | 0 |
Alias Born | 07/25/2016 |
Thursday, August 26, 2021 10:05:01 AM
I didn’t read it in detail, but I’m guessing the 14 mill raised was to (mostly) ramp up inventory. I hadn’t looked at their financials until now, as I was flipping it on that run-up, but their current ratio is outstanding; it’s 7-1 and their quick asset ratio is 5-1. Their gross profit margin is huge - 75%.
I don’t know if you’ve read about the CEO, but his background is incredible. They’ve got the foundation, now they have to build on it, although I wish I was in at $1, but that’s like a lottery…
I’m not going to wait long, though - I “gotta fish or cut bait.”
Shai Gozani is an impressive guy -
Shai N. Gozani, M.D., Ph.D.
Chairman of the Board, President, and Chief Executive Officer
Dr. Gozani founded NeuroMetrix, Inc. in 1996 as a spin-off from the Massachusetts Institute of Technology. He currently serves as Chairman of the board of directors and as our President and Chief Executive Officer. Dr. Gozani has led the Company from a venture capital backed start-up, through an initial public offering on Nasdaq, through development of a successful diagnostics business, and presently into the wearable technology sector. Over 2.5 million patients have benefited from the Company’s technology over the past 15 years.
Dr. Gozani has published over 30 peer-reviewed scientific articles and has been awarded 25 US and international patents. Dr. Gozani holds a B.A. degree in Computer Science, a M.S. degree in Electrical Engineering & Computer Science (Biomedical Engineering Focus) and a Ph.D. in Neurobiology, from the University of California, Berkeley. He also received an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at M.I.T.
Recent NURO News
- NeuroMetrix Announces Steps Taken to Enhance Shareholder Value • GlobeNewswire Inc. • 04/19/2024 12:00:00 PM
- NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy • GlobeNewswire Inc. • 03/14/2024 01:00:00 PM
- NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia • GlobeNewswire Inc. • 03/13/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:23:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:21:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:20:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:19:11 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/04/2024 09:12:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/01/2024 10:07:47 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/27/2024 09:45:07 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/27/2024 09:00:09 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/26/2024 10:41:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:15:08 PM
- NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/20/2024 07:49:16 PM
- NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call • GlobeNewswire Inc. • 02/15/2024 02:00:00 PM
- NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value • GlobeNewswire Inc. • 02/13/2024 02:00:00 PM
- NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID) • GlobeNewswire Inc. • 12/12/2023 02:00:00 PM
- NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) • GlobeNewswire Inc. • 12/05/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 02:33:08 PM
- NeuroMetrix Announces One-for-Eight Reverse Stock Split • GlobeNewswire Inc. • 11/20/2023 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/26/2023 08:20:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 11:11:44 AM
- NeuroMetrix Reports Q3 2023 Business Highlights • GlobeNewswire Inc. • 10/26/2023 11:00:00 AM
- NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call • GlobeNewswire Inc. • 10/23/2023 03:13:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM